Sodium‐glucose co‐transporter‐2 inhibitors and the risk of venous thromboembolism: A nationwide population‐based study and meta‐analysis

SGLT-2 inhibitors may be associated with a lower risk of venous thromboembolism compared to dipeptidyl peptidase-4 inhibitors in patients with diabetes.

• Data from 136,530 SGLT-2 inhibitor users was analyzed, alongside 598,280 DPP-4 inhibitor users and 5760 GLP-1 receptor agonist users.
• SGLT-2 inhibitor use is linked to a hazard ratio of 0.70 for venous thromboembolism risk compared to DPP-4 inhibitors.
• No significant difference in VTE risk was observed between SGLT-2 inhibitors and glucagon-like peptide-1 receptor agonists, with a hazard ratio of 1.39.
• A meta-analysis showed consistent results, with a hazard ratio of 0.71 for SGLT-2 inhibitors compared to DPP-4 inhibitors.
• The findings suggest SGLT-2 inhibitors may provide a safer option regarding VTE risk compared to DPP-4 inhibitors, but not compared to GLP-1 receptor agonists.

AI simplified